Originally published October 21 2005
Diabetes drug poses grave health risks for users, researchers say
by Mike Adams, the Health Ranger, NaturalNews Editor
The diabetes pill known as Pargluva, recently passed by the FDA, can double the risk for deaths, heart attacks and strokes.
- A new diabetes pill that appears headed for federal approval can double the risk for deaths, heart attacks and strokes, according to a study released online Thursday because of public safety concerns.
- The drug, known as muraglitazar, proposed for approval under the brand name Pargluva, was endorsed by a Food and Drug Administration panel last month.
- But Cleveland Clinic researchers who analyzed data the FDA made public before the panel vote found that patients taking Pargluva faced double the risk of death, heart attack or stroke, compared with those on dummy pills or a similar drug.
- The study was published Thursday morning on the Journal of the American Medical Association's Web site.
All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml